David Kavanagh

26.6k total citations · 2 hit papers
138 papers, 7.9k citations indexed

About

David Kavanagh is a scholar working on Immunology, Hematology and Nephrology. According to data from OpenAlex, David Kavanagh has authored 138 papers receiving a total of 7.9k indexed citations (citations by other indexed papers that have themselves been cited), including 115 papers in Immunology, 57 papers in Hematology and 48 papers in Nephrology. Recurrent topics in David Kavanagh's work include Complement system in diseases (112 papers), Renal Diseases and Glomerulopathies (46 papers) and Blood groups and transfusion (38 papers). David Kavanagh is often cited by papers focused on Complement system in diseases (112 papers), Renal Diseases and Glomerulopathies (46 papers) and Blood groups and transfusion (38 papers). David Kavanagh collaborates with scholars based in United Kingdom, United States and Switzerland. David Kavanagh's co-authors include Anna Richards, Tim Goodship, Timothy H.J. Goodship, John P. Atkinson, Andrew P. Herbert, Edwin Wong, Vicky Brocklebank, M. Kathryn Liszewski, Paul N. Barlow and Marina Noris and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

David Kavanagh

129 papers receiving 7.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome

2006 531 citations Marina Noris, David Kavanagh et al. profile →
The ExAC browser: displaying reference data information from over 60 000 exomes

2016 452 citations David Kavanagh et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
David Kavanagh	5.8k	3.3k	2.3k	1.1k	902	138	7.9k
Antonio M. Risitano	5.6k 1.0×	2.5k 0.7×	3.5k 1.5×	812 0.7×	1.9k 2.1×	200	8.1k
Scott A. Rollins	4.1k 0.7×	1.4k 0.4×	1.9k 0.8×	1.1k 1.0×	1.3k 1.4×	63	7.2k
Leendert A. Trouw	4.7k 0.8×	1.1k 0.3×	1.2k 0.5×	1.5k 1.4×	553 0.6×	218	9.8k
Russell P. Rother	4.7k 0.8×	2.0k 0.6×	2.4k 1.0×	989 0.9×	2.0k 2.2×	72	7.9k
Seza Özen	3.2k 0.6×	2.0k 0.6×	1.6k 0.7×	5.7k 5.1×	211 0.2×	335	9.5k
Ivona Aksentijevich	4.3k 0.7×	859 0.3×	1.4k 0.6×	5.9k 5.3×	230 0.3×	144	8.4k
Yoshihiro Fujimura	4.1k 0.7×	1.8k 0.5×	4.4k 1.9×	1.3k 1.1×	1.5k 1.7×	249	8.1k
Alexander Röth	2.9k 0.5×	1.4k 0.4×	1.9k 0.8×	528 0.5×	1.5k 1.7×	153	5.6k
Yves Pirson	1.2k 0.2×	2.0k 0.6×	796 0.3×	2.3k 2.1×	436 0.5×	200	7.4k
Gunnar Sturfelt	4.7k 0.8×	874 0.3×	871 0.4×	976 0.9×	363 0.4×	165	8.3k

Countries citing papers authored by David Kavanagh

Since Specialization

Citations

This map shows the geographic impact of David Kavanagh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Kavanagh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Kavanagh more than expected).

Fields of papers citing papers by David Kavanagh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Kavanagh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Kavanagh. The network helps show where David Kavanagh may publish in the future.

Co-authorship network of co-authors of David Kavanagh

This figure shows the co-authorship network connecting the top 25 collaborators of David Kavanagh. A scholar is included among the top collaborators of David Kavanagh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Kavanagh. David Kavanagh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

McGlasson, Sarah, Kayleigh M. Reid, Anna Klingseisen, et al.. (2025). Misdirected yet intact TREX1 exonuclease activity causes human cerebral and systemic small vessel disease. Brain. 148(8). 2981–2994.

Java, Anuja, Matthew A. Sparks, & David Kavanagh. (2025). Post-transplant Thrombotic Microangiopathy. Journal of the American Society of Nephrology. 36(5). 940–951. 2 indexed citations

Vale, Luke, Yemi Oluboyede, Andrew Bryant, et al.. (2025). Cost-effectiveness of lifelong eculizumab versus disease monitoring of aHUS. Nephrology Dialysis Transplantation. 41(2). 321–331.

Mallett, Grace, Isabel Y. Pappworth, Grant J. Logan, et al.. (2025). AAV-mHDM-FH: Safety and expression profile in two murine models of hyper-complement activation. Immunobiology. 230(4). 153002–153002.

Walsh, Patrick, Wioleta M. Zelek, Thomas Hoyler, et al.. (2025). The membrane attack complex drives thrombotic microangiopathy in complement mediated atypical hemolytic uremic syndrome. PubMed. 107(4). 700–713. 5 indexed citations

Kavanagh, David, Gema Ariceta, Marina Vivarelli, et al.. (2025). Current and Emerging Therapies for C3 Glomerulopathy and Primary (Idiopathic) Immune Complex Membranoproliferative Glomerulonephritis. Kidney International Reports. 11(1). 17–31.

Duineveld, Caroline, et al.. (2024). Kidney Transplantation in Patients With aHUS: A Comparison of Eculizumab Prophylaxis Versus Rescue Therapy. Transplantation. 109(3). 511–518. 3 indexed citations

Vivarelli, Marina, Andrew S. Bomback, Matthias Meier, et al.. (2023). Iptacopan in Idiopathic Immune Complex–Mediated Membranoproliferative Glomerulonephritis: Protocol of the APPARENT Multicenter, Randomized Phase 3 Study. Kidney International Reports. 9(1). 64–72. 9 indexed citations

Tschernoster, Nikolai, Florian Erger, Patrick R. Walsh, et al.. (2022). Unraveling Structural Rearrangements of the CFH Gene Cluster in Atypical Hemolytic Uremic Syndrome Patients Using Molecular Combing and Long-Fragment Targeted Sequencing. Journal of Molecular Diagnostics. 24(6). 619–631. 5 indexed citations

10.

Bryant, Andrew, Sonya Carnell, Thomas Chadwick, et al.. (2022). Safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome: protocol for a multicentre, open-label, prospective, single-arm study. BMJ Open. 12(9). e054536–e054536. 5 indexed citations

11.

Hallam, Thomas M, Vicky Brocklebank, Nikolaos Tzoumas, et al.. (2022). A novel method for real-time analysis of the complement C3b:FH:FI complex reveals dominant negative CFI variants in age-related macular degeneration. Frontiers in Immunology. 13. 1028760–1028760. 6 indexed citations

12.

Kurzawa‐Akanbi, Marzena, Long Xie, Dean Hallam, et al.. (2020). Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of AMD by restoring lysosomal function. Stem Cells Translational Medicine.

13.

Altmann, Thomas, Megan Torvell, Stephen Owens, et al.. (2020). Complement factor I deficiency. Neurology Neuroimmunology & Neuroinflammation. 7(3). 16 indexed citations

14.

Breno, Matteo, Nicolò Ghiringhelli Borsa, Fengxiao Bu, et al.. (2018). Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. The Journal of Immunology. 200(7). 2464–2478. 119 indexed citations

15.

Challis, Rachel, Troels Ring, Yaobo Xu, et al.. (2016). Thrombotic Microangiopathy in Inverted Formin 2–Mediated Renal Disease. Journal of the American Society of Nephrology. 28(4). 1084–1091. 29 indexed citations

16.

Ward, Sophie, Paula Bertram, Arthur Jackson, et al.. (2014). Autoantibodies to CD59, CD55, CD46 and CD35 are not associated with aHUS. Molecular Immunology. 61. 236–236. 1 indexed citations

17.

Kavanagh, David, Shreya Raman, & Neil Sheerin. (2014). Management of hemolytic uremic syndrome. F1000Prime Reports. 6. 119–119. 14 indexed citations

18.

Schmidt, Christoph Q., Andrew P. Herbert, David Kavanagh, et al.. (2008). A New Map of Glycosaminoglycan and C3b Binding Sites on Factor H. The Journal of Immunology. 181(4). 2610–2619. 172 indexed citations

19.

Richards, Anna, David Kavanagh, & John P. Atkinson. (2007). Inherited Complement Regulatory Protein Deficiency Predisposes to Human Disease in Acute Injury and Chronic Inflammatory StatesThe Examples of Vascular Damage in Atypical Hemolytic Uremic Syndrome and Debris Accumulation in Age‐Related Macular Degeneration. Advances in immunology. 96. 141–177. 60 indexed citations

20.

Moulton, Elizabeth A., David Kavanagh, Marie‐Agnès Dragon‐Durey, et al.. (2006). Genetic and Functional Analyses of Membrane Cofactor Protein (CD46) Mutations in Atypical Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology. 17(7). 2017–2025. 184 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact